Search
Fosigotifator
go.drugbank.com/drugs/DB19409InvestigationalFosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).
Ribostamycin
go.drugbank.com/drugs/DB03615ApprovedWithdrawnRibostamycin is an aminoglycoside antibiotic[A187166] isolated from _Streptomyces ribosidificus_[A187178] listed as one of the World Health Organization's critically important antimicrobials.[L9071]
Eprinomectin
go.drugbank.com/drugs/DB11405ExperimentalVet approvedCategories: Compounds used in a research, industrial, or household settingClocapramine
go.drugbank.com/drugs/DB09003ExperimentalClocapramine is an atypical antipsychotic of the imidobenzyl class which was introduced in Japan in 1974 for the treatment of schizophrenia. … In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic.
Ferulic acid
go.drugbank.com/drugs/DB07767InvestigationalCategories: Compounds used in a research, industrial, or household settingDeltamethrin
go.drugbank.com/drugs/DB13600ExperimentalCategories: Compounds used in a research, industrial, or household settingSuccinobucol
go.drugbank.com/drugs/DB05399InvestigationalAGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary artery disease.
Volinanserin
go.drugbank.com/drugs/DB16351InvestigationalVolinanserin is under investigation in clinical trial NCT00464243 (Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study).
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Adebrelimab
go.drugbank.com/drugs/DB16412InvestigationalAdebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer